



## Antidepressant Medication Management (AMM)

Performance for this measure is determined by the percentage of patients 18 and older who were treated with antidepressant medication, had a diagnosis of major depression, and who remained on an antidepressant for at least 180 days (6 months). AMM is a quality metric for our TennCare and BCBS Commercial patients. Exclusion will apply to patients receiving hospice care. Please review the following qualifying medications for this measure:

| Drug Category                    | Medications  |
|----------------------------------|--|
| Miscellaneous antidepressants    | • Bupropion • Vortioxetine<br>• Vilazodone   |
| Monoamine oxidase inhibitors     | • Isocarboxazid • Phenelzine<br>• Selegiline • Tranylcypromine   |
| Phenylpiperazine antidepressants | • Nefazodone • Trazodone   |
| Psychotherapeutic combinations   | • Amitriptyline-chlordiazepoxide<br>• Amitriptyline-perphenazine<br>• Fluoxetine-olanzapine  |
| SNRI antidepressants             | • Desvenlafaxine • Duloxetine<br>• Levomilnacipran • Venlafaxine   |
| SSRI antidepressants             | • Citalopram • Escitalopram • Fluoxetine<br>• Fluvoxamine • Paroxetine • Sertraline  |
| Tetracyclic antidepressants      | • Maprotiline • Mirtazapine  |
| Tricyclic antidepressants        | • Amitriptyline • Amoxapine • Clomipramine<br>• Desipramine • Doxepin (>6 mg) • Imipramine<br>• Nortriptyline • Protriptyline • Trimipramine |

| TennCare AMM Performance                            |               |          |                |
|---|---------------|----------|----------------|
| (Data based off claims processed as of August 2021) |               |          |                |
| Amerigroup  | UHC Community | BlueCare | 2021 Threshold |
| 23%   | 52%           | 35%      | ≥ 40%          |

Note: These score reflect the entire Tax ID, not just a singular clinic.